We forecast WuXi's revenue growth to be slower than that of other well-established peers. The risk is high that the US Biosecure Act will become law, and we expect global pharmaceutical or ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

A representation of the country’s rapidly developing capability can be seen in the example of WuXi Biologics ... of manufacturing capacity for biologics. Similar signs of growth can be seen ...

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million ...

Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...

Talents People are WuXi Biologics' greatest assets ... Sustainability The Group has integrated Sustainability as a core pillar of its business growth strategy, earning widespread recognition from ...

HONG KONG, March 25, 2025 /PRNewswire/ -- WuXi Biologics ... to the biologics industry, fast growing technology platforms including ADCs and bispecific antibodies; (iii) growth of research ...